These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33827877)

  • 1. Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
    Mar E; Taylor K; Mollee P
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33827877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
    Dejhansathit S; Suvannasankha A
    J Investig Med High Impact Case Rep; 2019; 7():2324709619832332. PubMed ID: 30947547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute deep vein thrombosis with concurrent new diagnosis of AL-amyloid-induced factor X deficiency.
    Paton EL; Barisic S; Sabile JM; Medvedova E
    BMJ Case Rep; 2024 Jun; 17(6):. PubMed ID: 38839408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency.
    Lewis AR; Peffley N; Klompas AM; Ashrani AA
    Transfusion; 2023 Sep; 63(9):1773-1777. PubMed ID: 37427705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.
    Patel G; Hari P; Szabo A; Rein L; Kreuziger LB; Chhabra S; Dhakal B; D'Souza A
    Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):10-14. PubMed ID: 30879471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis.
    Enjeti AK; Walsh M; Seldon M
    Haemophilia; 2005 Sep; 11(5):535-8. PubMed ID: 16128899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.
    Chitimus DM; Berling E; Garderet L; Venturelli N; Malfatti E; Authier FJ; Nicolas G; Laforêt P; Lefeuvre C
    Eur J Neurol; 2023 Mar; 30(3):745-748. PubMed ID: 36403110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, clinical characteristics and treatment outcome of factor X deficiency in a consecutive cohort of primary light-chain amyloidosis.
    Gao YJ; Shen KN; Chang L; Feng J; Mao YY; Zhang L; Cao XX; Zhou DB; Li J
    Leuk Res; 2022 Sep; 120():106917. PubMed ID: 35849875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal bleeding due to acquired factor IX and X deficiency: a rare complication of primary amyloidosis; case report and review of the literature.
    Ericson S; Shah N; Liberman J; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):e81-6. PubMed ID: 24290671
    [No Abstract]   [Full Text] [Related]  

  • 11. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
    Wu X; Miao HL; Zhu TN; Feng J; Zhang L; Mao YY; Zhou DB; Cao XX; Li J
    Amyloid; 2019 Dec; 26(4):255-256. PubMed ID: 31526149
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
    Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
    Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis.
    Mahmood S; Blundell J; Drebes A; Hawkins PN; Wechalekar AD
    Blood; 2014 May; 123(18):2899-900. PubMed ID: 24786460
    [No Abstract]   [Full Text] [Related]  

  • 15. Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
    Marcatti M; Mauri S; Tresoldi M; Sabbadini MG; Vigano'D'Angelo S; Safa O; Rugarli C; D'Angelo A
    Thromb Res; 1995 Nov; 80(4):333-7. PubMed ID: 8585046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systemic light chain amyloidosis with acquired factor X deficiency: a case report].
    Li L; Zhou F; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):506. PubMed ID: 22967401
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
    Rybinski B; Kocoglu M
    Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone.
    Levin M; Chokas W
    N Engl J Med; 1987 Oct; 317(18):1155-6. PubMed ID: 3657882
    [No Abstract]   [Full Text] [Related]  

  • 19. Acquired factor X deficiency in systemic amyloidosis: management of two cases.
    Chaudhary P; Wakim J; Khadim H; Karumbaiah KK; Gajra A
    Haemophilia; 2013 Nov; 19(6):e375-6. PubMed ID: 24033815
    [No Abstract]   [Full Text] [Related]  

  • 20. Daratumumab in AL amyloidosis.
    Wechalekar AD; Sanchorawala V
    Blood; 2022 Dec; 140(22):2317-2322. PubMed ID: 35507692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.